Skip to main content
Sign In

Department of Psychiatry

Department of Psychology

Lynn L. Johnson, PharmD

    Lynn L. Johnson, PharmD

Bldg. 500, Level 4, Rm. 4317

Phone:  303-724-6221

Email:  Dr. Johnson

 

Lynn L. Johnson, PharmD

Instructor


 

ACADEMIC APPOINTMENTS, PROFESSIONAL POSITIONS, AND HONORS

Positions and Employment:

Pharmacist Intern, King Soopers Pharmacy, Denver, CO, 1996-1997 

Pharmacist Intern Presbyterian/St. Lukes Hospital, Denver, CO, 1997-1998            

Pharmacy Manager, Costco Corporation, Littleton, CO, 1999-2000            

Pharmacy Manager, Cub Pharmacy, Lakewood, CO, 2000-2001            

PRN pharmacist, Costco Corporation, Littleton, CO, 2000-2005                    

Regular Fellow, UCHSC, Denver, CO, 2002-2005                  

Instructor, UCDenver, Denver, CO, 2005-Present             

 

Other Experience and Professional Memberships:

National Community Pharmacy Association, 1995 

American Pharmaceutical Association, 1995-1998 

Colorado Pharmacy Association, 1995-1999            

President, Academy of Students of Pharmacy, Denver, CO, 1996

 

Honors:

School of Pharmacy Alumni Fundraiser, 1995 

Distinguished Service Award, Academy of Students of Pharmacy, UCHSC, 1996                                       

McKesson Leadership Award, Outgoing President, Academy of Students of Pharmacy, UCHSC, 1997                     

Outstanding Professional Achievement Award, 1996, University of Colorado School of Pharmacy, 1997  

 

Teaching Activities:

Not applicable. 

 

Clinical Activities:

Not applicable. 

 

SCHOLARSHIPS AND PUBLICATIONS

Publications:

Hannigan A, Meyer JD, Johnson L, Manning MC, Catalano C.  The phage lambda terminase enzyme: 2.  Refolding of the gpNu1 subunit from the detergent-denatured and guanidinium hydrocholoride-denatured state yields different oligiomerization states and altered protein stabilities.  Int J Biol Macromolecules.  23:37-48, 1998.

Olincy A, Johnson LL, Ross RG,  Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia.  Psychiatry Res.  117:223-236, 2003.

Olincy,A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J Zerbe, GO, Leonard S, Stevens KE Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.  Proof-of-concept Trial of an α7 Nicotinic Agonist in Schizophrenia. Archives of General Psychiatry, 63:630-38, 2006.

Freedman R,  Olincy A, Buchanan RW, Harris JG,  Gold JM, Johnson L,  Allensworth D, Guzman A, Clement B, Ball P, Kutnick J, Pender V, Martin L, Stevens KE, Wagner B, Zerbe G, Soti, Kem WF. Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia, American Journal of Psychiatry, 165(8):1040-7, 2008

Tregellas, J.R., Olincy, A., Johnson, L., Tanabe, J., Shatti, S., Martin, L.F., Singel, D., Du, Y.P., Soti, F., Kem, W.R., Freedman, R.  Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia. Neuropsychopharmacology (In Press).

 

Grants and Contracts:

Ongoing

NIMH P50 MH086383-01, Freedman (PI), 8/01/09- 7/31/14, $2,102,458

Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia”

The aims of this Translational Conte Center are to characterize the role of the alpha7 nicotinic acetylcholine receptor in the brain and its dysfunction and to use this biology to continue development of a new therapeutic strategy to improve the treatment of cognitive dysfunction and negative symptoms in persons who have schizophrenia .  This emerging information about the developmental role of the receptor will be used to initiate a perinatal intervention for pregnant women and their children to decrease the risk of schizophrenia.  The Center develops strategies to image inhibitory function hemodynamically and electrophysiologically, in both adults and infants, and it develops new animal models, including the transfer of human CHRNA7 into mice and models of developmental abnormalities induced by the immune response to infections.

 

Veterans Affairs Medical Research Service, VA Merit Review, Freedman (PI), 10/1/09 - 9/30/13 

“Nicotinic Receptors and Schizophrenia”

This proposal will examine the effects of 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A) and Neurocognitive improvement in Veterans with schizophrenia

 

Completed

Silvio O.Conte Center 5 P50 MH068582-02, Freedman, (PI),  09/27/04- 06/30/09

“Molecular Neurobiology of Schizophrenia”

This proposal examines the neurobiological effects of genetic polymorhisms in genes associated with Schizophrenia.

Role: Coordinator

 

NIMH R01 MH65588-01, grant 1, Olincy (PI), 3/15/03-3/15/08

Genetics of Endophenotypes and Schizophrenia

This grant examines the inheritance of  6 endophenotypes and their relation to the inheritance of schizophrenia.

Role:  Co-investigator

 

NARSAD Junior Investigator Award, Johnson (PI), 7/1/05-7/1/07

The Effects of Cannabis Use in People with Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

This grant examines the effects of acute dronabinol on verbal learning, inhibition, P50 gating and smooth pursuit eye tracking.

Role:  Principal Investigator

 

NIMH RO1 MH059565, Freedman (PI), 0/1/98-7/31/07

Molecular Genetics of Schizophrenia

This project proposes to examine the genetic differences between 5,000 probands with schizophrenia and a comparison group of normal controls.

Role: Coordinator

 

NIMH R01 MH61412   Freedman (PI)2/01/01-11/01/04

Nicotinic Agonists in Schizophrenia

This grant is to use DMXB-A as a proof of principal in the nicotinic receptor hypothesis in schizophrenia.

Role:  Co-investigator